NEW DELHI: Biocon will fully integrate its biosimilars arm, Biocon Biologics into the parent, in a deal valuing the unit at $5.5 billion. The move is aimed at creating a unified biopharma powerhouse, and to strengthen its global position to lead in diabetes, oncology, and immunology — therapeutic areas that together account for nearly 40% of global pharma revenues, Kiran Mazumdar-Shaw, executive chairperson, Biocon said on Saturday. Biocon will acquire the remaining stake in Biocon Biologics from Serum Institute Life Sciences (Serum), Tata Capital and Activ Pine through a share swap of 70.28 Biocon shares for every 100 Biocon Biologics shares, at a price of Rs 405.78 per Biocon share. Further, Biocon will acquire the residual stake held by Mylan (Viatris) for $815 million, split betw

See Full Page